‘Gemini Therapeutics Merger Company Disc Medicine Granted FDA Orphan Designation For Erythropoietic Protoporphyria Treatment’
https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=916222
Why Invitae Climbed Around 279%; Here Are 98 Biggest Movers From Yesterday
Gainers
Invitae Corporation (NYSE: NVTA) surged 278.5% to close at $8.63 after the company reported better-than-expected Q2 EPS.
Biotech Daily: Cancer Causing Impurities In Merck’s Diabetic Drug, Vir Bio-GSK Shun FDA Submission Plans For COVID-19 Treatment, Aethlon’s Monkeypox Trial
Here's a roundup of top developments in the biotech space over the last 24 hours:
Gemini Therapeutics And Disc Medicine Announce Merger Agreement
Merger to create NASDAQ-listed, clinical-stage biopharmaceutical company focused on advancing Disc Medicine’s portfolio of hematology programs
Combined company is expected to have approximately $175 million of